News

Ferrari N.V. Makes Significant Progress in Share Buyback

Ferrari N.V. Makes Significant Progress in Share Buyback

Ferrari N.V. Update on Its Buyback Program

Ferrari N.V. (NYSE/EXM: RACE) has recently provided an update regarding its ongoing share buyback initiative, reflecting its commitment to enhancing shareholder value. As a part of a larger strategy involving an investment of approximately Euro 2 billion, this initiative was first announced during the Capital Markets Day in 2022. This update pertains to the latest tranche of the buyback, known as the Fifth Tranche, introduced as a Euro 250 million allocation.

Recent Share Purchases

Under this buyback program, Ferrari has completed a series of notable purchases on the Euronext Milan (EXM). Between October 28 and November 1, 2024, the Company bought back a total of 18,300 common shares. Here's a summary of the transactions executed during this period:

Purchase Summary

The buybacks included transactions over multiple days, with specific details as follows:

  • October 28, 2024: 3,600 shares at an average price of €452.7015
  • October 29, 2024: 3,600 shares at an average price of €452.9684
  • October 30, 2024: 3,700 shares at an average price of €445.1321
  • October 31, 2024: 3,700 shares at an average price of €440.1004
  • November 1, 2024: 3,700 shares at an average price of €442.2036

All these purchases collectively amounted to a total expenditure exceeding €8 million. This detailed action confirms Ferrari's proactive approach in maintaining a robust investment framework aimed at maximizing shareholder return.

Total Investments to Date

From the onset of the Fifth Tranche through November 1, 2024, Ferrari has committed a total of Euro 171,825,124.84 towards the purchase of 416,350 shares solely on the EXM. In addition, the Company executed purchases on the NYSE totaling USD 45,452,667.64, which equates to approximately Euro 41 million. This brings the overall share repurchased to a remarkable tally.

Current Treasury Holdings

As of early November 2024, the Company holds a total of 14,678,349 common shares in treasury, which represents 5.71% of its entire issued share capital. This figure includes both common shares and special voting shares, adjusted for those allocated through the Company's equity incentive programs. Over the years, since the inauguration of the buyback program in mid-2022, Ferrari has already purchased a staggering 3,855,585 of its own shares across both the EXM and NYSE, reaching total expenditures of approximately €1.14 billion.

Availability of Detailed Transaction Information

For shareholders and interested parties looking for more comprehensive insights into Ferrari's buyback activities, a complete overview of these transactions is readily available on Ferrari’s corporate website, specifically under the Buyback Programs section. This enables transparency and allows stakeholders to stay informed about the Company's financial strategies and shareholder value enhancements.

Frequently Asked Questions

What is the purpose of Ferrari's share buyback program?

The share buyback program is designed to enhance shareholder value by reducing the number of outstanding shares, thus potentially increasing the earnings per share.

How much has Ferrari invested in share buybacks so far?

As of November 1, 2024, Ferrari has invested a total of Euro 171,825,124.84 in share buybacks under the Fifth Tranche.

What percentage of shares does Ferrari currently hold in treasury?

Ferrari currently holds 14,678,349 common shares in treasury, which is 5.71% of its total issued share capital.

Where can I find more information about Ferrari's buyback program?

More details and a comprehensive overview of the buyback program can be found on Ferrari’s corporate website under the Buyback Programs section.

How does the share buyback impact shareholders?

By executing share buybacks, Ferrari aims to provide a higher value for remaining shareholders through improved earnings per share and the commitment to returning capital to investors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 66

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Darden Faces Class Action Over Reimbursement Failures

Updated Category News Views 239

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 176

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 221

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 187

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 35

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading

Top 5 Most Recently Viewed Articles

Vor Bio's Exploration of Strategic Alternatives for Growth

Updated Category News Views 213

Vor Bio Announces Exploration of Strategic Alternatives Today, Vor Bio, a clinical-stage cell and genome engineering company, has taken significant steps to enhance shareholder value. The decision comes at a time when the clinical data from its major programs suggests that reevaluating its approach could be beneficial in the face of challenging fundraising conditions....

Continue Reading
Kraig Biocraft Achieves Record Production in Spider Silk Fibers

Updated Category News Views 56

Kraig Biocraft Laboratories' Milestone in Spider Silk Production Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneering firm renowned for its innovative developments in spider silk-based fibers, is thrilled to share the successful conclusion of its fourth production cycle for the year. This cycle represents a remarkable achievement, showcasing record-breaking...

Continue Reading
Gen X Faces Retirement Challenges: Understanding the Crisis

Updated Category News Views 282

Gen X’s Coming Retirement Crunch Gen X—often called the “sandwich generation”—is being pulled in two directions at once and edging toward a retirement problem many don’t fully see. With money, time, and attention split between family and work, long-term savings can drift to the back burner. The worry isn’t abstract; it’s about whether the money will be...

Continue Reading
Luxurious Villa Spectre: A $55 Million Icon of Elegance

Updated Category News Views 342

Villa Spectre: A $55 Million Marvel of Luxury Living Villa Spectre has recently captured the spotlight as the highest-priced sale in the area, setting a remarkable benchmark in luxury real estate. This impressive estate was sold for $55,000,000, showcasing the allure and opulence that the elite have come to expect from high-end properties. A Visionary Creation Designed by...

Continue Reading
Mosaic Minerals Shifts Focus to Gold with Amanda Acquisition

Updated Category News Views 333

Mosaic Minerals Re-prioritizes Focus on Gold Exploration Mosaic Minerals Corporation (CSE: MOC) is making a strategic pivot in its exploration efforts. The company has announced the cessation of its lithium exploration initiatives, particularly those in Jamésie, Quebec. Instead, Mosaic is setting its sights on more promising ventures in gold and nickel, specifically...

Continue Reading